Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: A good idea or a grave error?

Clinical and Translational Oncology

Volumn 13, Issue 3, 2011, Pages 209-210

  Balañá, Carmen ^a   Etxaniz, Olatz ^a   Bugés, Cristina ^a   Martínez, Alex ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; IRINOTECAN; PLACEBO; PROCARBAZINE; TEMOZOLOMIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERABILITY; EUROPE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; GLIOMA; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG APPROVAL; EUROPE; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958206587     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0642-9     Document Type: Letter

References (13)

1. Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents, Vol. IX. IARC Scientific Publication, Lyon
2. Kleihues P, Soylemezoglu F, Schauble B et al (1995) Histopathology, classification, and grading of gliomas. Glia 15:211-221
3. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL (2007) Epidemiology of brain tumors. Neurol Clin 25:867-890, vii
4. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
5. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
6. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
7. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593 (Pubitemid 30636298)
8. Brada M, Hoang-Xuan K, Rampling R et al (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266 (Pubitemid 32223879)
9. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771 (Pubitemid 29415233)
10. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012
11. Taillibert S, Hoang-Xuan K, Guiu B et al (2010) Bevacizumab (b) with irinotecan (i) in recurrent glioblastoma (GBM): a national retrospective cohort of the ANOCEF (association des Neurooncologues d'expression française) group. Ann Oncol 21:viii329 (Abstract 1056P)
12. Grude F, Campone M, Soulie P et al (2010) Bevacizumab and irinotecan in recurrent malignant glioma: Results of a French retrospective cohort study omit of 264 patients in real practice! Ann Oncol 21:viii329 (Abstract 1058P)
13. Gil JM, De las Penas R, Reynes G et al (2010) Bevacizumab plus irinotecan in recurrent malignant glioma showed high overall survival in a retrospective study. Neuro Oncol 12:iv1-iv136:53 (Abst NO-73)